The project TargetAMD is funded by the European Commission in the context of the Seventh Framework Programme classified to the topic health.
TargetAMD brings together an interdisciplinary team of outstanding scientists from 8 European countries. Five SMEs (located in France, Hungary, Spain, Italy and The Netherlands), three academic partners, four Hospital and Research Ophthalmology Departments represent the international consortium of 13 partners.
The project is led by the University of Geneva, Professor Gabriele Thumann, Department of Ophthalmology and assisted by professional EU project management of RWTH Aachen University, Ms. Maria Perdikomati-Dahmen.
The projects` aim is to develop a transposon-based gene therapy for the exudative form of Age-related Macular Degeneration (AMD), and translate the treatment into the First-In-Man clinical trial (phase Ib/ IIa) in Europe. The multifaceted consortium represents specialists offering a broad panel of experiences and knowledge in the pathology and treatment of AMD with key competences in the fields of genetic engineering, molecular and cell biology, in vivo modelling, ocular surgery, clinical studies, quality control and GMP-grade production.
The international consortium of 13 partners:
Key competences of the whole consortium are shown in table 1 below: